Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Macular Edema in Subjects Who Completed the Three Year VISTA-DME Trial .
Latest Information Update: 06 Jun 2019
Price :
$35 *
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Acronyms Endurance; Endurance 1 Trial
- 01 May 2017 Status changed from active, no longer recruiting to completed.
- 27 Feb 2017 Planned End Date changed from 1 Jan 2017 to 1 Feb 2017.
- 27 Feb 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Feb 2017.